We used the lowest dose of SU6656 that efficiently reduces SFK activity in melanoma cells (10 μM), and we previously showed that this dose has no direct effect on ABL1 or ABL2 as it does not reduce their activities in cells that lack SFK expression25. Here, ABL2 is linked to melanoma.